Amarin Corp Plc (AMRN)

[ggwpq]

The new guideline seems to say if previously approved drug "D+E" is an NCE, then new drug "D+E+F" could not be an NCE. It doesn't say much about new drug "D" or new drug "E" which might serve an unmet medical need, e.g., TG between 200 and 500 population. The way I see is if FDA say no on NCE for Vascepa, only Amarin will protest so it's easy for FDA to say no. On the other hand, if FDA say yes on NCE, lots of Amarin's competitors will protest so FDA must take its time and make the NCE determination iron clad. So my vote is YES on NCE.